FindTrial
Sign In

Value and mechanism of REV-ERBa signaling pathway in substantia nigra aging and pathogenesis of Parkinson's disease

Value and mechanism of REV-ERBa signaling pathway in substantia nigra aging and pathogenesis of Parkinson's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200062859
Enrollment
Unknown
Registered
2022-08-21
Start date
2022-08-08
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease, Geriatric Diseases

Interventions

NA:NA

Sponsors

Shanghai Tongji Hospital, School of Medicine, Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who are diagnosed with PD, controls who are age-matched with PD and without exclusion criteria; 2. Willing to sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Sleep apnea syndrome; 2. A history of deep brain stimulation surgery; 3. Unable to complete clinical evaluation; 4. Take sleeping pills and other psychiatric drugs.

Design outcomes

Primary

MeasureTime frame
REV-ERBa;ß-galactosidase;TNF-a;SOD, superoxide dismutase;Clock protein;—

Countries

China

Contacts

Public ContactXijin Wang

Shanghai Tongji Hospital, School of Medicine, Tongji University

wangxijin2004@163.com+86 13651627382

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026